Enhancing Diabetic Macular Edema Treatment Outcomes: Exploring the ESASO Classification and Structural OCT Biomarkers

Giacomo Panozzo,Maria V. Cicinelli,Giulia Dalla Mura, Diana Giannarelli,Maria Vadalà,Vincenza Bonfiglio, Giovanni Bellisario, Francesco Bandello

Ophthalmology and Therapy(2024)

引用 0|浏览5
暂无评分
摘要
This study assessed the European School of Advanced Studies in Ophthalmology (ESASO) classification’s prognostic value for diabetic macular edema (DME) in predicting intravitreal therapy outcomes. In this retrospective, multicenter study, patients aged > 50 years with type 1 or 2 diabetes and DME received intravitreal antivascular endothelial growth factor (anti-VEGF) agents (ranibizumab, bevacizumab, and aflibercept) or steroids (dexamethasone). The primary outcome was visual acuity (VA) change post-treatment, termed as functional response, measured 4–6 weeks post-third anti-VEGF or 12–16 weeks post-steroid injection, stratified by initial DME stage. Of the 560 eyes studied (62
更多
查看译文
关键词
Diabetic macular edema,Optical coherence tomography,Steroid,Anti-VEGF,ESASO classification,OCT Biomarkers,Treatment outcomes in DME,Retinal Neurovascular Unit
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要